The House Oversight Committee will mark up a far-reaching bill on May 15 that, if passed, could force many US biopharma companies to cut ties with WuXi and several other Chinese life sciences contractors, a congressional aide confirmed to Endpoints News.
The markup signals building, bipartisan momentum on the closely-watched bill that could have wide-ranging implications for dozens of companies. A similar bill passed out of the Homeland Security and Governmental Affairs Committee earlier this spring.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.